KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Common Equity (2016 - 2025)

Historic Common Equity for Fulgent Genetics (FLGT) over the last 11 years, with Q3 2025 value amounting to $1.1 billion.

  • Fulgent Genetics' Common Equity fell 79.39% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 79.39%. This contributed to the annual value of $1.1 billion for FY2024, which is 25.29% down from last year.
  • Latest data reveals that Fulgent Genetics reported Common Equity of $1.1 billion as of Q3 2025, which was down 79.39% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Fulgent Genetics' Common Equity peaked at $1.3 billion during Q1 2022, and registered a low of $801.6 million during Q1 2021.
  • In the last 5 years, Fulgent Genetics' Common Equity had a median value of $1.1 billion in 2024 and averaged $1.2 billion.
  • As far as peak fluctuations go, Fulgent Genetics' Common Equity surged by 95778.18% in 2021, and later plummeted by 1121.21% in 2024.
  • Over the past 5 years, Fulgent Genetics' Common Equity (Quarter) stood at $1.2 billion in 2021, then rose by 8.92% to $1.3 billion in 2022, then dropped by 10.53% to $1.1 billion in 2023, then decreased by 0.25% to $1.1 billion in 2024, then fell by 0.65% to $1.1 billion in 2025.
  • Its Common Equity stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.1 billion for Q1 2025.